FY2025 EPS Estimates for DNTH Increased by Cantor Fitzgerald

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Cantor Fitzgerald lifted their FY2025 EPS estimates for Dianthus Therapeutics in a research report issued on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($3.16) per share for the year, up from their previous estimate of ($3.46). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Other equities analysts have also issued research reports about the stock. Guggenheim reiterated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $21.97 on Monday. Dianthus Therapeutics has a fifty-two week low of $18.13 and a fifty-two week high of $33.77. The stock has a fifty day moving average of $22.44 and a 200-day moving average of $24.76. The company has a market capitalization of $650.25 million, a price-to-earnings ratio of -8.79 and a beta of 1.82.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Dianthus Therapeutics during the third quarter valued at about $556,000. Barclays PLC grew its position in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares during the last quarter. HighVista Strategies LLC bought a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $542,000. State Street Corp increased its stake in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.